Of note, an in vitro screening revealed that a mutation on the allosteric drug binding pocket or αC-helix of MEK confers resistance to allosteric MEK inhibition, and, consistent with this, MEKi-resistant MEK1P124L mutation was detected in selumetinib/AZD6244-resistant BRAFV600E melanoma of patients [71]. Here, MAP2K7 is linked to melanoma.